SUBSCRIBE
SUBSCRIBE
News   Policy

US FDA Staff Says Genentech, Inc.'s Avastin Brain Cancer Data Unclear

March 30, 2009 | 
1 min read
WASHINGTON, March 27 (Reuters) - It is difficult to tell how well brain cancer patients responded to Genentech Inc's cancer drug Avastin in early studies from the company, U.S. Food and Drug Administration staff said in documents released on Friday.
Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Female hand showing thumbs up gesture on blue background, art collage. Positive hand sign. Fashion collage in the style of Thumbs up magazine. Contemporary art. Modern design.
Approvals
Boehringer Wins Speedy Lung Cancer Approval Under Commissioner’s Priority Program
February 27, 2026
 · 
2 min read
 · 
Tristan Manalac
Finding Talented People. Big Hands with Magnifying Glass Recruiting People. vector
FDA
Prasad Under Probe for Promoting Workplace Toxicity, Staffers Say
February 27, 2026
 · 
2 min read
 · 
Tristan Manalac
Digital compass. Business strategic explorer, Vision crisis, Mission path, Agency creative, Digital strategy, Market decision, Achievement strategy, Financial stock, Company vision concepts
Policy
FDA Policy Tracker 2026: One-Trial Drug Applications, Guidelines for Personalized Therapies
February 27, 2026
 · 
7 min read
 · 
Heather McKenzie
FDA commissioner Marty Makary speaking on a Youtube video, wearing a dark suit and a blue tie
Regulatory
Makary Defends FDA’s Decision-Making Amid Contentious Rare Disease Rejections
February 27, 2026
 · 
2 min read
 · 
Tristan Manalac